Ezra Cohen, MD
Ezra Cohen, MD, is an Associate Professor of Medicine (Hematology/Oncology) and co-Director of the Head and Neck Cancer Program since 2010. He also serves as the Fellowship Program Director of Hematology/Oncology. Previous to his appointments at the University of Chicago, Dr. Cohen was a family physician at the University of Toronto in Ontario, Canada and completed his residency in Internal Medicine at the Long Island Jewish Medical Center at Albert Einstein College of Medicine and a fellowship in Hematology/Oncology at the University of Chicago Hospitals.
Dr. Cohen’s research interests focus on clinical and laboratory studies of upper aerodigestive tract malignancies with an emphasis on novel therapeutics and signaling in head and neck cancers. He has a unique understanding of the molecular biology underlying the disease and the associated clinical challenges and potential application of new therapeutics. Dr. Cohen has published extensively on head and neck cancer, especially in the areas of induction (neoadjuvant) chemotherapy, epidermal growth factor receptor inhibitors, mTOR inhibitors, and other novel targeted agents. He serves as the principal investigator on a multi-national phase 3 study investigating the impact of induction chemotherapy on survival in patients with locally advanced squamous cell carcinoma of the head and neck (the DeCIDE trial). He also serves as the principal investigator on a multi-institutional, randomized phase 2 study testing the effect on response rates of adding the mTOR inhibitor everolimus to induction chemotherapy. In addition, Dr. Cohen serves as the principal investigator on the EPOC study testing erlotinib versus placebo to prevent oral cancers in high-risk patients.
Within the University of Chicago, Dr. Cohen has had numerous responsibilities, including serving as a member of the Executive Committee of the Section of Hematology/Oncology and on the Faculty Oversight Committee (FOC) for the Biostatistics Laboratory (BL). He has also served as a reviewer for UCCCC Protocol Specific Research Funds and Breast SPORE Developmental Research Projects. Dr. Cohen also serves on numerous national and international professional bodies including the Head and Neck Cancer Steering Committee and Recurrent/Metastatic Disease Task Force, the International Thyroid Oncology Group, and the Board of Directors of the Head and Neck Cancer Alliance. Dr. Cohen also currently serves as Editor-in-Chief of the journal Oral Oncology, on the International Advisory Board of Lancet Oncology, and on the Editorial Board of several journals including Clinical Cancer Research, and World Journal of Clinical Oncology.
Dr. Dralle graduated University of Heidelberg in 1976 and was made full Professor and Chairman of the Department of Surgery, University Hospital Halle and Medical Faculty University of Halle-Wittenberg in 1994. He is a member of various committees (e.g. research, habilitation, appointments for professors and chairman). He has won numerous awards including Best paper Award, world Journal of Surgery. Dr. Dralle has held many positions in National and International Societies including as President of the International Association of Endocrine Surgeons (2005-2007) and President of the European Society of Endocrine Surgeons (2008 – 2010) and is an Honorary Membr of the German Society of Nuclear Medicin and the European Society of Surgery.
Sebastiano Filetti, MD is a full professor of Internal Medicine at Sapienza University of Rome. Dr. Filetti attended and completed his medical training at the Catania University. He also completed a one year Fellowship in Nuclear Medicine at the Brussels Free-University and in Metabolism Department at the London University Middlesex Hospital. He joined University of California San Francisco as Fulbright-Hays fellow and thereafter appointed as assistant professor and later as Associate Professor in 1985. He is member of the American Thyroid Association since 1980 and Endocrine Society since 1983. Dr. Filetti’s current clinical interests include endocrine and thyroid cancer, diabetes and endocrine/metabolic diseases. Dr. Filetti’s research interests focus on thyroid tumorigenesis and the strategic implications of the genetic and epigenetic abnormalities in endocrine tumors. In particular he is actively involved in research focusing on the identification and clinical validation of thyroid cancer biomarkers to achieve a better cancer risk stratification. He is also investigating the genetic basis of familial and sporadic thyroid cancer. Dr. Filetti is currently a principal investigator in several clinical trials concerning new target-therapy drugs.
Dr. Clive Grant is a consultant at the Mayo Clinic Rochester, Professor of Surgery in the College of Medicine, Mayo Clinic and Program Director for the Endocrine Surgery Fellowship. He graduated from the University of Colorado in 1975 with his M.D. degree and completed his surgical residency at the Mayo Clinic in 1980. He has been a consultant and surgeon at Mayo Clinic Rochester since that time. In the past he has served as Chairman of the Division of General and Gastroenterologic Surgery and Vice-Chair of the Department of Surgery at Mayo Clinic. Dr. Grant has a specific interest in surgical endocrine diseases and breast cancer. He has published approximately 300 peer-reviewed articles, book chapters, and books during his career. He was the Recorder of the Western Surgical Association, past President of the American Association of Endocrine Surgeons, and member of the American Surgical Association, International Association of Endocrine Surgeons, Central Surgical Association, among other organizations.
Yuri Nikiforov, M.D., Ph.D
Dr. Nikiforov is currently Professor of Pathology at the University of Pittsburgh Medical Center where he also serves as Director of the Division of Molecular Anatomic Pathology. His research program is funded by the National Institute of Health and focused on molecular genetics of thyroid cancer, thyroid cancer diagnostics, and molecular mechanisms of chromosomal rearrangements induced ionizing radiation. He has published more than 100 peer-reviewed articles and more than 15 book chapters, and is senior editor of the book “Diagnostic Pathology and Molecular Genetics of the Thyroid” published by Wolters Kluwer Health. He is the recipient of the 2007 Van Meter Award from the American Thyroid Association and an elected member of the American Society for Clinical Investigation.
R Michael Tuttle, MD
Dr. Tuttle, originally from Kentucky, attended medical school at the University of Louisville in Louisville Kentucky. He went on to do his Internship and Residency in Internal Medicine at Dwight David Eisenhower Army Medical Center in Augusta Georgia. This was followed by a two year fellowship in Endocrinology and one year of laboratory based training in molecular biology at Madigan Army Medical Center in Tacoma Washington.
After 3 years as a staff endocrinologist at Madigan Army Medical Center, he transferred to Walter Reed Army Medical Center in Washington DC. At Walter Reed he served as Assistant Chief of the Thyroid clinic, and Assistant Chief of the Department of Clinical Investigations. Upon leaving the Army, Dr Tuttle joined the Endocrine Service at Memorial Sloan Kettering Cancer Center in August of 1999. Dr Tuttle’s clinical and research interests continue to center on the management of advanced thyroid cancer.